Recombinant Mouse Osteopontin protein (His Tag)

Species

Mouse

Purity

>95 %, SDS-PAGE

Tag

His Tag

Activity

EC50: 165-660 ng/mL

Cat no : Eg0317



Product Information

Purity >95 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Immobilized Mouse Osteopontin (His tag) at 0.5 μg/mL (100 μL/well) can bind Human ITGAV (GST tag) with a linear range of 165-660 ng/mL.
Expression HEK293-derived Mouse Osteopontin protein Leu17-Asn294 (Accession# Q547B5) with a His tag at the C-terminus.
GeneID 20750
Accession Q547B5
PredictedSize 34.5 kDa
SDS-PAGE 50-60 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Osteopontin (OPN), also known as SPP1, is a secreted glycophosphoprotein that belongs to the small integrin-binding ligand N-linked glycoprotein (SIBLING) family. Originally isolated from bone. OPN has been found in kidneys, vascular tissues, biological fluids, and various tumor tissues. It can interact with CD44 and integrins and regulate diverse biological processes. It has a multifaceted role in bone development and remodeling, and is also involved in the inflammatory and immune response, oncogenesis and cancer progression.

References:

1. Denhardt DT, et al. (2001). J Clin Invest. 107(9):1055-61. 2. Fisher LW, et al. (2001). Biochem Biophys Res Commun. 280(2):460-5. 3. Rittling SR, et al. (2004). Br J Cancer. 90(10):1877-81. 4. Rangaswami H, et al. (2006). Trends Cell Biol. 16(2):79-87.